TY - JOUR
T1 - The association between age-related macular degeneration and renal cell carcinoma
T2 - A nested case-control study
AU - Keizman, Daniel
AU - Yang, Yu Xiao
AU - Gottfried, Maya
AU - Dresler, Hadas
AU - Leibovitch, Ilan
AU - Haynes, Kevin
AU - Mamtani, Ronac
AU - Boursi, Ben
N1 - Publisher Copyright:
© 2017 American Association for Cancer Research.
PY - 2017/5/1
Y1 - 2017/5/1
N2 - Background: Overexpression of VEGF is implicated in the pathogenesis of both renal cell carcinoma (RCC) and age-related macular degeneration (AMD). We evaluated the association between AMD and RCC risk. Methods:Weconducted a matched case-control study within a population-representative database from the United Kingdom. Study cases were defined as individuals with any diagnostic code of RCC. For every case, four eligible controls were matched on age, sex, practice site, calendar time, and duration of follow-up. Exposure of interest was diagnosis of AMD prior to cancer diagnosis. Adjusted ORs and 95% confidence intervals (CI) for RCC were estimated using conditional logistic regression. In a secondary analysis, we evaluated the association between other retinopathies and RCC andAMDand the hypovascular pancreatic cancer. Results: The study population included 1,547 patients with RCC and 6,066 matched controls. Median follow-up time was 6 years (IQR, 3-9). AMD diagnosis was associated with a significantly increased RCC risk (OR, 1.89; 95% CI, 1.09-3.29). In contrast, there was no association between other retinopathies and RCCrisk (OR, 0.8; 95%CI, 0.56-1.15). AMD was associated with a lower risk for pancreatic cancer (OR, 0.47; 95% CI, 0.35-0.64). Conclusions: Patients withAMDmay be at higher risk for RCC. Providers should be aware of this potential link and consider screening for RCC within this population. Impact: Providers should be aware of the potential link between AMD and RCC.
AB - Background: Overexpression of VEGF is implicated in the pathogenesis of both renal cell carcinoma (RCC) and age-related macular degeneration (AMD). We evaluated the association between AMD and RCC risk. Methods:Weconducted a matched case-control study within a population-representative database from the United Kingdom. Study cases were defined as individuals with any diagnostic code of RCC. For every case, four eligible controls were matched on age, sex, practice site, calendar time, and duration of follow-up. Exposure of interest was diagnosis of AMD prior to cancer diagnosis. Adjusted ORs and 95% confidence intervals (CI) for RCC were estimated using conditional logistic regression. In a secondary analysis, we evaluated the association between other retinopathies and RCC andAMDand the hypovascular pancreatic cancer. Results: The study population included 1,547 patients with RCC and 6,066 matched controls. Median follow-up time was 6 years (IQR, 3-9). AMD diagnosis was associated with a significantly increased RCC risk (OR, 1.89; 95% CI, 1.09-3.29). In contrast, there was no association between other retinopathies and RCCrisk (OR, 0.8; 95%CI, 0.56-1.15). AMD was associated with a lower risk for pancreatic cancer (OR, 0.47; 95% CI, 0.35-0.64). Conclusions: Patients withAMDmay be at higher risk for RCC. Providers should be aware of this potential link and consider screening for RCC within this population. Impact: Providers should be aware of the potential link between AMD and RCC.
UR - http://www.scopus.com/inward/record.url?scp=85019206205&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-16-0759
DO - 10.1158/1055-9965.EPI-16-0759
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 28062400
AN - SCOPUS:85019206205
SN - 1055-9965
VL - 26
SP - 743
EP - 747
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 5
ER -